NCT07777822
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07777822
Title Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC (RASolve 308)
Acronym RASolve 308
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Revolution Medicines, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Alaska Oncology and Hematology RECRUITING Anchorage Alaska 99508 United States Details
Helios CR, Inc. - The Oncology Institute of Hope and Innovation - Fort Lauderdale RECRUITING Fort Lauderdale Florida 33316 United States Details
Florida Clinical Trials Group, LLC RECRUITING Plantation Florida 33322 United States Details
Florida Clinical Trials Group RECRUITING Plantation Florida 33322 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field